|
Gene: ARSI |
Gene summary for ARSI |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARSI | Gene ID | 340075 |
Gene name | arylsulfatase family member I | |
Gene Alias | ASI | |
Cytomap | 5q32 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5FYB1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
340075 | ARSI | C04 | Human | Oral cavity | OSCC | 1.84e-03 | 3.82e-01 | 0.2633 |
340075 | ARSI | C21 | Human | Oral cavity | OSCC | 5.90e-28 | 9.08e-01 | 0.2678 |
340075 | ARSI | C30 | Human | Oral cavity | OSCC | 2.18e-49 | 1.86e+00 | 0.3055 |
340075 | ARSI | C38 | Human | Oral cavity | OSCC | 9.76e-03 | 4.71e-01 | 0.172 |
340075 | ARSI | C51 | Human | Oral cavity | OSCC | 2.53e-21 | 9.81e-01 | 0.2674 |
340075 | ARSI | C06 | Human | Oral cavity | OSCC | 3.14e-16 | 1.66e+00 | 0.2699 |
340075 | ARSI | SYSMH2 | Human | Oral cavity | OSCC | 2.21e-03 | 1.28e-01 | 0.2326 |
340075 | ARSI | SYSMH3 | Human | Oral cavity | OSCC | 6.64e-06 | 2.01e-01 | 0.2442 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARSI | SNV | Missense_Mutation | c.1353C>A | p.Asn451Lys | p.N451K | Q5FYB1 | protein_coding | tolerated(0.29) | benign(0.05) | TCGA-55-7725-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARSI | SNV | Missense_Mutation | novel | c.88G>T | p.Asp30Tyr | p.D30Y | Q5FYB1 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.697) | TCGA-55-8616-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARSI | SNV | Missense_Mutation | c.745C>A | p.Leu249Met | p.L249M | Q5FYB1 | protein_coding | tolerated(0.17) | benign(0.314) | TCGA-67-4679-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ARSI | SNV | Missense_Mutation | rs745477091 | c.481C>T | p.Arg161Cys | p.R161C | Q5FYB1 | protein_coding | deleterious(0.01) | benign(0.075) | TCGA-75-5126-01 | Lung | lung adenocarcinoma | Female | Unknown | III/IV | Unknown | Unknown | SD |
ARSI | SNV | Missense_Mutation | novel | c.139N>A | p.Pro47Thr | p.P47T | Q5FYB1 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ARSI | SNV | Missense_Mutation | novel | c.585N>T | p.Glu195Asp | p.E195D | Q5FYB1 | protein_coding | tolerated(1) | benign(0.042) | TCGA-91-6835-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARSI | SNV | Missense_Mutation | c.1555N>T | p.Ala519Ser | p.A519S | Q5FYB1 | protein_coding | tolerated(0.07) | probably_damaging(0.916) | TCGA-21-5787-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
ARSI | SNV | Missense_Mutation | c.1243N>C | p.Val415Leu | p.V415L | Q5FYB1 | protein_coding | deleterious(0.02) | benign(0.426) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ARSI | SNV | Missense_Mutation | novel | c.742N>C | p.Tyr248His | p.Y248H | Q5FYB1 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-63-A5MM-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
ARSI | deletion | Frame_Shift_Del | novel | c.1144delN | p.Ala382ProfsTer46 | p.A382Pfs*46 | Q5FYB1 | protein_coding | TCGA-75-5147-01 | Lung | lung adenocarcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |